Sickle-Cell Anemia Therapeutics Market in the US 2018-2022
About this market
Sickle- cell anemia treatment is associated with high cost medications in the US. To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care. Technavio’s analysts have predicted that the sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.
Recent product approvals for sickle- cell anemia
Due to fewer product availability in the US for the treatment of sickle- cell anemia, hence these recently approved products drive the market over the forecast period.
Limited number of approved drugs
The availability of very limited approved therapies for the treatment of sickle- cell anemia id the US is expected to hamper the growth of the market during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the sickle-cell anemia therapeutics market in the US during the 2018-2022, view our report.
The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Sickle-Cell Anemia Therapeutics Market in the US 2018-2022
Technavio recognizes the following companies as the key players in the sickle-cell anemia therapeutics market in the US: Bristol-Myers Squibb, Emmaus Medical, Medunik USA.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the research on the development of gene therapy to treat sickle- cell anemia is a new approach.
According to the report, one of the major drivers for this market is the awareness’s programs are expected to increase the focus on disease diagnosis and treatment options. Therefore, leading to the growth of the sickle- cell anemia therapeutics market in the US over the forecast period.
Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are expected to restrict the market growth during the forecast period.
and Medunik USA
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook